Strain-dependent alterations in the expression of folate pathway genes following teratogenic exposure to valproic acid in a mouse model

American Journal of Medical Genetics

Volumn 70, Issue 3, 1997, Pages 303-311

  Finnell, Richard H ^a   Wlodarczyk, Bogdan C ^a   Craig, Johanna C ^a   Piedrahita, Jorge A ^a   Bennett, Gregory D ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Gene expression; Mice; Teratogenicity; Valproic acid

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLATE BINDING PROTEIN; HOMOCYSTEINE; METHIONINE; RNA; VALPROIC ACID;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; FOLIC ACID DEFICIENCY; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; MOUSE; NEURAL TUBE DEFECT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRAIN DIFFERENCE; TERATOGENESIS;

5,10-METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANIMALS; DATA INTERPRETATION, STATISTICAL; MICE; MODELS, BIOLOGICAL; NEURAL TUBE DEFECTS; OXIDOREDUCTASES; POLYMORPHISM, GENETIC; SPECIES SPECIFICITY; TERATOGENS; VALPROIC ACID;

ANIMALIA; MURINAE;

EID: 0030986598     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8628(19970613)70:3<303::AID-AJMG17>3.0.CO;2-P     Document Type: Article

References (50)

1. Anderson RGW, Kamen BA, Rothberg KG, Lacey SW (1992): Photocytosis: Sequestration and transport of small molecules by caveolae. Science 255:410-411.
2. Ardinger HH, Atkin JF, Blackston RD, Elsas LJ, Clarren SK, Livingstone S, Flannery DB, Pellock JM, Harrod MJ, Lammer EJ, Majewski F, Schinzel A, Toriello H, Hanson JW (1988): Verification of the fetal valproate syndrome phenotype. Am J Med Genet 29:171-185.
3. Brigle KE, Houghton MT, Goldman ID (1991): Characterization of two cDNAs encoding folate binding proteins from L1210 murine leukemia cells. J Biol Chem 226:17243-17249.
4. Brigle KE, Seither RL, Westin EH, Goldman ID (1994a): Increased expression and genomic organization of a folate binding protein homologous to the human placental isoform in L1210 murine leukemia cell lines with a defective reduced folate carrier. J Biol Chem 269:4267-4272.
5. Brigle KE, Spinell ME, Westin EH, Goldman ID (1994b): Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells. Biochem Pharmacol 47:337-345.
6. Czeizel AE, Dudás I (1992): Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 327:1832-1835.
7. Danielson PE, Forss-Petter S, Brow MA, Calavetta L, Douglass J, Milner RJ, Sutcliffe JG (1988): p1B15: A cDNA clone of the rat mRNA encoding cyclophilin. DNA 7:261-267.
8. Dansky LV, Finnell RH (1991): Parental epilepsy, anticonvulsant drugs and reproductive outcome: Epidemiological and experimental findings spanning three decades. II. Human studies. Reprod Toxicol 5:281-299.
9. de Franchis R, Sebastio G, Mandato C, Andria G, Mastroiacovo P (1995): Spina bifida, 677C-T mutation, and the role of folate. Lancet 346:1703.
10. DiLiberti JH, Farndon PA, Dennis NR, Curry CJR (1984): The fetal valproate syndrome. Am J Med Genet 19:473-481.
11. Eberwine JH, Spencer CM, Miyashiro K, Mackler SA, Finnell RH (1992a): cDNA synthesis in situ: Methods and applications. In Wu G (ed): "Methods in Enzymology." Vol. 216. New York: Academic Press, pp 80-100.
12. Eberwine JH, Yeh H, Miyashiro K, Cao Y, Nair S, Finnell RH, Zeittel M, Coleman P (1992b): Analysis of gene expression in single live neurons. Proc Natl Acad Sci USA 89:3010-3014.
13. Finnell RH (1981): Phenytoin-induced teratogenesis: A mouse model. Science 211:483-484.
14. Finnell RH (1991): Genetic differences in susceptibility to anticonvulsant drug-induced developmental defects. Pharmacol Toxicol 69:223-227.
15. Finnell RH, vanWaes M, Bennett GD, Eberwine JH (1993): Lack of concordance between heat shock proteins and the development of tolerance to teratogen-induced neural tube defects. Devel Genet 14:137-147.
16. Finnell RH, Abbott LC, Taylor SM (1989): The fetal hydantoin syndrome: Answers from a mouse model. Reprod Toxicol 3:127-133.
17. Finnell RH, Bennett GD, Karras SB, Mohl VK (1988): Common hierarchies of susceptibility to the induction of neural tube defects by valproic acid and its 4-propyl-4-pentenoic acid metabolite. Teratology 38:313-320.
18. Finnell RH, Dansky LV (1991): Parental epilepsy, anticonvulsant drugs and reproductive outcome: Epidemiological and experimental findings spanning three decades. I. Animal studies. Reprod Toxicol 5:281-299.
19. Finnell RH, Moon SP, Abbott LC, Golden JA, Chernoff GF (1986): Strain differences in heat induced neural tube defects in mice. Teratology 33:247-252.
20. Finnell RH, Yerby MS, Nau H (1995): General principles: Teratogenicity of antiepileptic drugs. In Levy RH, Mattson RH, Meldrum BS (eds): "Antiepileptic Drugs," 4th ed. New York: Raven Press, pp 209-230.
21. Jaeger-Roman E, Deichl A, Jakob S, Hartmann A, Koch S, Rating D, Steldinger R, Nau H, Helge H (1986): Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 108:997-1004.
22. Janz D (1975): The teratogenic risk of antiepileptic drugs. Epilepsia 16: 159-169.
23. Johnson RA, Wichern DW (1992): In Conmy SR (ed): "Applied Multivariate Statistical Analysis." Englewood Cliffs, NJ: Prentice Hall, pp 356-395.
24. Kamen BA, Wang MT, Streckfuss AJ, Peryea X, Anderson RGW (1988): Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. J Biol Chem 263:13602-13609.
25. Lammer EJ, Sever LE, Oakley GP Jr. (1987): Teratogen update: Valproic acid. Teratology 35:465-473.
26. Lindhout D, Meinardi H, Meijer JWA, Nau H (1992): Antiepileptic drugs and teratogenesis in two consecutive cohorts: Changes in prescription policy paralleled by changes in pattern of malformations. Neurology 42(Suppl 5):94-110.
27. Neter J, Wasserman W, Kutner MH (1989): Some basic results in probability and statistics. In Irwin RD (ed): "Applied Linear Regression Models." Boston: Irwin, pp 10-40.
28. Ou CY, Stevenson RE, Brown VK, Schwartz CE, Allen WP, Khoury MJ, Rozen R, Oakley GP Jr, Adams MJ Jr (1996): 5,10-methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Med Genet 63:610-614.
29. Page ST, Owen WC, Price K, Elwood PC (1993): Expression of the human placental folate receptor transcript is regulated in human tissues: Organization and full nucleotide sequence of the gene. J Mol Biol 229: 1173-1183.
30. Prakash M, Murty MN (1995): A genetic approach for selection of (near-) optimal subsets of principal components for discrimination. Pattern Recog Lett 16(8):781-787.
31. Rao CR (1973): "Linear Statistical Inference and Its Applications," 2nd ed. New York: Wiley, pp 78-147.
32. Robert E (1982): Valproic acid and spina bifida: A preliminary report - France. MMWR 31:565-566.
33. Robert E, Guibaud P (1982): Maternal valproic acid and congenital neural tube defects. Lancet ii:937.
34. Rohlf JF, Bookstein FL (1990): Traditional morphometrics. In Rohlf JF, Bookstein FL (eds): "Proceedings of the Michigan Morphometrics Workshop." Ann Arbor: University of Michigan Museum of Zoology, pp 77-125.
35. Rosa FW (1991): Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 324:674-677.
36. Rothberg KG (1990): The glycophospholipid-linked folate receptor internalized folate without entering the clathrin-coated pit endocytotic pathway. J Cell Biol 110:637-649.
37. SAS Institute (1990): "SAS/STAT User's Guide Release 6.03." North Carolina: SAS Institute, pp 677-771, 891-996, 1241-1263.
38. Seller MJ, Embury S, Polani PE, Adinolfi M (1979): Neural tube defects in curly-tail mice. II. Effect of maternal administration of vitamin A. Proc R Soc Lond [Biol] 206:95-107.
39. Shaw GM, Jensvold NG, Wasserman CR, Lammer EJ (1994): Epidemiologic characteristics of phenotypically distinct neural tube defects among 0.7 million California births, 1983-1987. Teratology 49:143-149.
40. Smithells RW, Nevins NC, Seller MJ, Sheppard S, Harris R, Read AP, Fielding DW, Walker S, Schorah CJ, Wild J (1983): Further experience of vitamin supplementation for the prevention of neural tube defect recurrences. Lancet i:1027-1031.
41. Snell GD, Fekete E, Hummel KP (1948): The relation of mating, ovulation, and the estrus smear in the house mouse to the time of day. Anat Rec 76:30-54.
42. Sokal RR, Rohlf FJ (1981): "Biometry," 2nd ed. San Francisco: W.H. Freeman.
43. Taylor LE, Bennett GD, Finnell RH (1995): Altered gene expression in murine branchial arches following in utero exposure to retinoic acid. J Cranio Genet Dev Biol 15:13-25.
44. Trotz M, Wegner C, Nau H (1987): Valproic acid-induced neural tube defects: Reduction by folinic acid in the mouse. Life Sci 41:103-110.
45. van der Put N, Steegers-Theunissen R, Frosst P, Trijbels FJM, Eskes TKAB, van den Heuvel LP, Mariman ECM, den Heyer M, Rozen R, Blom HJ (1995): Mutated 5,10-methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 346:1070-1071.
46. Wegner C, Nau H (1991): Diurnal variation of folate concentrations in mouse embryo and plasma: The protective effect of folinic acid on valproic acid-induced teratogenicity is time dependent. Reprod Toxicol 5:465-471.
47. Wegner C, Nau H (1992): Alteration of embryonic folate metabolism by valproic acid during organogenesis: Implications for mechanism of teratogenesis. Neurology 42(Suppl 5):17-24.
48. Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings DS, Kamen BA (1992): Cellular localization of the folate receptor: Potential role in drug toxicity and folate homeostasis. Cancer Res 52:6708-6711.
49. Werler MM, Shapiro S, Mitchell AA (1993): Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 269:2847-2852.
50. Wlodarczyk B, Bennett GD, Calvin JA, Finnell RH (1996): Arsenic-induced changes in transcription factor gene expression: Implications for abnormal neural development. Dev Genet 18:306-315.